Introduction of the Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma (2023 Edition)

References

[1] Singal AG,Yarchoan M.AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.Hepatology2023;78:1922-65. PMCID:PMC10663390

[2] NCCN Clinical Practice Guidelines in Oncology-Hepatocellular Carcinoma. Available from: http://www.nccn.org [Last accessed on 23 Jan 2024]

[3] Fan J.Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular CarcinomaChinese College of SurgeonsCommittee of Liver CancerChinese Anti-Cancer Association;Liver Cancer GroupSociety of Oncology, Chinese Medical AssociationChinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma(2023 edition).Chin J Dig Surg2023;22:437-48

[4] Sun HC,Zhou J.Clinical practice status of the adjuvant therapy in hepatocellular carcinoma (HCC): a survey of Chinese hepatobiliary surgeons.J Clin Oncol2022;40:e16127

[5] Bai X,Liang T.Preliminary data of a prospective study on the safety and efficacy of donafinib combined with anti-PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma (HCC).J Clin Oncol2022;40:e16131

[6] Qin S,Cheng AL.Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.Lancet2023;402:1835-47